Results 131 to 140 of about 61,606 (299)

Gentiana lutea root aqueous extract mitigates hydroxyurea-induced genotoxicity through antioxidative action and DNA repair: an in vitro study in healthy human peripheral blood mononuclear cells

Arhiv za Higijenu Rada i Toksikologiju
Hydroxyurea is a chemotherapeutic agent used to treat various conditions, including sickle cell anaemia and myeloproliferative malignancies. However, it has adverse genotoxic effects on normal cells.
Radošević Ksenija, Kostić Mila, Janić Marijana, Jovanović Ivan, Živković Maja, Šobot Ana Valenta, Tričković Jelena Filipović   +6 more
doaj   +1 more source

Genetic Contribution to Asthma Informs Acute Chest Syndrome Pathophysiology and Risk Stratification

American Journal of Hematology, Volume 101, Issue 5, Page 961-971, May 2026.
ABSTRACT Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) occurring in ~50% of patients, some presenting frequent episodes. We lack tools to identify patients at high risk of ACS occurrence or frequent episodes. Epidemiological studies have found an association between asthma and ACS, but whether this link is causal is ...
Sara El Aouhel, Vanessa Bellegarde, Stennio Da Silva Faria, Tristan St‐Laurent, Estelle Lecluze, Anne‐Laure Pham Hung d’Alexandry d’Orengiani, Frédéric Galactéros, Pablo Bartolucci, Marc‐André Legault, Guillaume Lettre, Thomas Pincez   +10 more
wiley   +1 more source

Mutations In RAD27 Define A Potential Link Between G₁ Cyclins And DNA Replication [PDF]

, 1995
The yeast Saccharomyces cerevisiae has three G1 cyclin (CLN) genes with overlapping functions. To analyze the functions of the various CLN genes, we examined mutations that result in lethality in conjunction with loss of cln1 and cln2.
Cross, Frederick R., , \u2778, Vallen, Elizabeth Ann   +1 more
core   +1 more source

Genetic modulation of fetal hemoglobin in hydroxyurea‐treated sickle cell anemia [PDF]

, 2017
Milena Magalhães Aleluia, Rayra Pereira Santiago, Caroline Conceição da Guarda, Teresa Cristina Cardoso Fonseca, Fábia Idalina Neves, Regiana Souza Quinto, Camylla V. B. Figueiredo, Sètondji Cocou Modeste Alexandre Yahouédéhou, Rodrigo Mota de Oliveira, Júnia Raquel Dutra Ferreira, Bruno A. V. Cerqueira, Cynara Gomes Barbosa, Jacqueline N. Milton, Martin H. Steinberg, Marilda de Souza Gonçalves   +14 more
openalex   +1 more source

Stroke From Paradoxical Embolism in a Young Patient With Sickle‐Cell Disease and High Fetal Hemoglobin: A Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 5, May 2026.
Acute infarcts and microvascular ischemic changes in the brain of a young patient with Sickle‐Cell Disease despite High Fetal Hemoglobin. ABSTRACT Sickle‐cell disease (SCD) is characterized by abnormal hemoglobin (Hb) polymerization, leading to erythrocyte sickling and microvascular obstruction.
Yi Hui Luo, Navid Zuberi, Angelo Rizzolo, Margaret Warner, Stephane Isnard, Jean‐Pierre Routy   +5 more
wiley   +1 more source

Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for Their Synthesis

ChemistryEurope, Volume 4, Issue 5, May 2026.
Screening of chemical libraries has over the past decades become a cornerstone of drug discovery. Today, a broad range of chemical libraries exist but they are often not well described in terms of diversity. This review describes current efforts which aim to visualize chemical diversity in compound collections and discuss current trends in synthetic ...
Tobias N. Hansen, Nils J. V. Hansen
wiley   +1 more source

Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease

Hastings Center Report, Volume 56, Issue 3, Page 9-14, May–June 2026.
Abstract In December 2023, the U.S. Food and Drug Administration approved gene‐editing therapies as sickle cell disease treatments. Such approvals for gene‐editing not only mark radical scientific innovations for populations living with sickle cell disease (SCD) across the United States but also generate an expectation of a potential cure—the end or ...
Jada Wiggleton‐Little, Shameka Poetry Thomas, Kristin Walters, Consuela Albright   +3 more
wiley   +1 more source

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, Volume 116, Issue 5, Page 545-557, May 2026.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

G‐CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution

American Journal of Hematology, Volume 101, Issue 6, Page 1178-1181, June 2026.
Akshay Sharma, Allistair Abraham, Monica Bhatia, María Cancio, Sonali Chaudhury, Selim Corbacioglu, Gregory M. T. Guilcher, Ashish O. Gupta, Rabi Hanna, Matthew M. Heeney, Tami John, Lakshmanan Krishnamurti, James L. LaBelle, Hemalatha G. Rangarajan, Shalini Shenoy, Elizabeth Stenger, Crawford Strunk, Courtney D. Fitzhugh   +17 more
wiley   +1 more source

Whole Blood Transcriptomic Analysis of Sickle Cell Trait

European Journal of Haematology, Volume 116, Issue 5, Page 535-544, May 2026.
ABSTRACT Sickle cell trait (SCT) is the heterozygous carrier state for the HBB missense variant which causes sickle cell disease (SCD). SCT has been associated with increased risk of venous thromboembolism and chronic kidney disease as well as alterations in clinical laboratory parameters. To investigate differential gene expression in SCT, we used RNA
Mari Johnson, Yanwei Cai, Ana Gabriela Vasconcelos, Peter Orchard, Paul L. Auer, Guillaume Lettre, Jia Wen, Nora Franceschini, Charles Kooperberg, Wei Sun, Li Hsu, Laura M. Raffield, Alex P. Reiner   +12 more
wiley   +1 more source